In vitro pharmacological profile of nonpeptide CRF1 receptor antagonists, CRA1000 and CRA1001

European Journal of Pharmacology

Volumn 371, Issue 2-3, 1999, Pages 205-211

  Chaki, Shigeyuki ^a   Okuyama, Shigeru ^a   Nakazato, Atsuro ^a   Kumagai, Toshihito ^a   Okubo, Taketoshi ^a   Ikeda, Yoko ^a   Oshida, Yuichi ^a   Hamajima, Yuko ^a   Tomisawa, Kazuyuki ^a  

^a Medicinal Research Laboratories   (Japan)

Author keywords

AtT 20 cell; cAMP formation; CRA1000; CRA1001; CRF1 receptor antagonist

Indexed keywords

2 [N (2 BROMO 4 ISOPROPYLPHENYL) N ETHYLAMINO] 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 6 METHYLPYRIMIDINE; 4 [4 (3 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 PYRIDINYL] 2 [N ETHYL N (4 ISOPROPYL 2 METHYLTHIOPHENYL)AMINO] 6 METHYLPYRIMIDINE; BUTYL[2,5 DIMETHYL 7 (2,4,6 TRIMETHYLPHENYL) 7H PYRROLO[2,3 D]PYRIMIDIN 4 YL]ETHYLAMINE; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; CORTICOTROPIN RELEASING FACTOR RECEPTOR; CYCLIC AMP; SRC 241; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORTICOTROPIN RELEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; IN VITRO STUDY; MALE; MEMBRANE BINDING; NONHUMAN; PRIORITY JOURNAL; RAT; SHEEP;

ADRENOCORTICOTROPIC HORMONE; ANIMALS; BRAIN; CORTICOTROPIN-RELEASING HORMONE; COS CELLS; CYCLIC AMP; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; FRONTAL LOBE; HYPOTHALAMUS; MALE; PROTEIN BINDING; PYRIDINES; PYRIMIDINES; RATS; RATS, WISTAR;

EID: 0032961601     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00120-X     Document Type: Article

References (32)

1. Berridge C.W., Dunn A.J. CRF and restraint-stress decrease exploratory behavior in hypophysectomized mice. Pharmacol. Biochem. Behav. 34:1989;517-519.
2. Bilezikjian L.M., Vale W.W. Glucocorticoids inhibit corticotropin-releasing factor-induced production of adenosine 3′,5′-monophosphate in cultured anterior pituitary cells. Endocrinology. 113:1983;657-662.
3. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
4. 1 receptor mRNA expression. J. Neurosci. 15:1995;6340-6350.
5. Chen R., Lewis K.A., Perrin M.H., Vale W.W. Expression cloning of a human corticotropin-releasing factor receptor. Proc. Natl. Acad. Sci. USA. 90:1993;8967-8971.
6. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162:1987;156-159.
7. De Souza E.B. Corticotropin-releasing factor receptors in the rat central nervous system: characterization and regional distribution. J. Neurosci. 7:1987;88-100.
8. Dunn A.J., Berridge C.W. Physiological and behavioral responses to corticotropin-releasing factor administration: is CRF a mediator of anxiety or stress responses? Brain Res. Rev. 15:1990;71-100.
9. Felgner P.L., Gadek T.R., Holm M., Roman R., Chan H.W., Wenz H., Northrop J.P., Ringold G.M., Danielsen M. Lipofection: a highly efficient, lipid-mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. USA. 84:1987;7413-7417.
10. 3H ]dopa in various regions of the brain J. Neurochem. 13:1966;655-669.
11. 125I -Tyr°-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2α receptors Mol. Pharmacol. 50:1996;679-686.
12. Hook V.Y., Heisler S., Sabol S.L., Axelrod J. Corticotropin releasing factor stimulates adrenocorticotropin and β-endorphin release from AtT-20 mouse pituitary tumor cells. Biochem. Biophys. Res. Commun. 106:1982;1364-1371.
13. 1 receptor antisense oligonucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59:1995;229-239.
14. Lovenberg T.W., Liaw C.W., Grigoriadis D.E., Clevenger W., Chalmers D.T., De Souza E.B., Oltersdorf T. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl. Acad. Sci. USA. 92:1995;836-840.
15. 2β receptor mRNAs are differentially distributed between the rat central nervous system and peripheral tissues. Endocrinology. 136:1995;4139-4142.
16. Lundkvist J., Chai Z., Teheranian R., Hasanvan H., Bartfai T., Jenck F., Widmer U., Moreau J.-L. A nonpeptidic corticotropin releasing factor receptor antagonist attenuates fever and exhibits anxiolytic-like activity. Eur. J. Pharmacol. 309:1996;195-200.
17. 1 receptor antagonist. Eur. J. Pharmacol. 323:1997;21-26.
18. Menzachi F., Howard R.L., Heinrichs S.C., Vale W.W., Rivier J., Koob G.F. Characterization of a novel and potent corticotropin-releasing factor antagonist in rats. J. Pharmacol. Exp. Ther. 269:1994;564-572.
19. Nemeroff C.B., Widerlov E., Bissette G., Walleus H., Karlsson I., Eklund K., Kilts C.D., Loosen P.T., Vale W.W. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science. 226:1984;1342-1344.
20. Owens M.J., Nemeroff C.B. Physiology and pharmacology of corticotropin releasing factor. Pharmacol. Rev. 43:1991;425-473.
21. Perrin M., Donaldson C., Chen R., Blount A., Berggren T., Bilezikjian L., Sawchenko P., Vale W.W. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl. Acad. Sci. USA. 92:1995;2969-2973.
22. Rivier C., Plotsky P.M. Mediation by corticotropin-releasing factor (CRF) of adrenohypophysial hormone secretion. Annu. Rev. Physiol. 48:1986;475-494.
23. Sarnyai Z., Biro E., Gardi J., Vecsernyes M., Julesz J., Telegdy G. Brain corticotropin-releasing factor mediates 'anxiety-like' behaviour induced by cocaine withdrawal in rats. Brain Res. 675:1995;89-97.
24. Schulz D.W., Mansbach R.S., Sprouse J., Braselton J.P., Collins J., Corman M., Dunaiskis A., Faraci S., Schmidt A.W., Seeger T., Seymour P., Tingley F.D., Winston E.N., Chen Y.L., Heym J. CP-154,526: a potent and selective nonpeptide antagonist of corticotropin releasing factor receptors. Proc. Natl. Acad. Sci. USA. 93:1996;10477-10482.
25. Schwartz J., Gibson S., White A. Regulation of ACTH secretory pathways in cultured pituitary cells. Am. J. Physiol. 261:1991;C793-C798.
26. Skutella T., Montkowski A., Stohr T., Probst J.C., Landgraf R., Holsboer F., Jirikowski G.F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell. Mol. Neurobiol. 14:1994;579-588.
27. Skutella T., Criswell H., Moy S., Probst J.C., Breese G.R., Jirikowski G.F., Holsboer F. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rats. NeuroReport. 5:1994;2181-2185.
28. Spina M., Merlo-Pich E., Chan R.K.W., Basso A.M., Rivier J., Vale W.W., Koob G.F. Appetite-suppressing effects of urocortin, a CRF-related neuropeptide. Science. 273:1996;1561-1564.
29. Stenzel-Poore M.P., Heinrichs S.C., Rivest S., Koob G.F., Vale W.W. Overproduction of corticotropin-releasing factor in transgenic mice: a genetic model of anxiogenic behavior. J. Neurosci. 14:1994;2579-2584.
30. Takebe Y., Seiki M., Fujisawa J., Hoy P., Yokota K., Arai K., Yoshida M., Arai N. An efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus Type 1 long terminal repreat. Mol. Cell. Biol. 8:1988;466-472.
31. Vale W.W., Spiess J., Rivier C., Rivier J. Characterization of a 41-amino acid residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science. 213:1981;1394-1397.
32. Webster E.L., Lewis D.B., Torry D.J., Zachman E.K., Rice K.C., Chrousos G.P. In vivo and in vitro characterization of antalarmin, a nonpeptide corticotropin-releasing hormone (CRH) antagonist: suppression of pituitary ACTH release and peripheral inflammation. Endocrinology. 137:1996;5747-5750.